Matthias Watzka
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients.
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 12, 2020
Recurrent Intracranial Bleed in 3 Siblings: Short of a Shot of Vitamin K!
Journal: Journal of pediatric hematology/oncology
Published: July 31, 2019
Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Journal: Nature structural & molecular biology
Published: May 23, 2016
VKCFD2 - from clinical phenotype to molecular mechanism.
Journal: Hamostaseologie
Published: June 16, 2015
Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family.
Journal: Nutrients
Published: May 18, 2015
VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?
Journal: Nutrients
Published: May 18, 2015
Tris(3-hydroxypropyl)phosphine is superior to dithiothreitol for in vitro assessment of vitamin K 2,3-epoxide reductase activity.
Journal: Analytical biochemistry
Published: October 26, 2014
Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.
Journal: Thrombosis research
Published: August 22, 2014
Last Updated: 09/26/2026